A Clinical Viewpoint on the Use of Targeted Therapy in Advanced Gastric Cancer

SIMPLE SUMMARY: Outcomes for patients with advanced gastric cancer continue to be unsatisfactory despite the inclusion of new targeted therapies in the treatment options. The effectiveness of targeted therapies is limited for a particular subset of the population. This is related to the fact that specific biomarkers are present in a very small percentage of patients with advanced gastric cancer. It is paramount to conduct further research focused on identifying new molecular targets, as this can significantly improve the effectiveness of advanced-stage therapy. ABSTRACT: The development of therapies for advanced gastric cancer (GC) has made significant progress over the past few years. The identification of new molecules and molecular targets is expanding our understanding of the disease’s intricate nature. The end of the classical oncology era, which relied on well-studied chemotherapeutic agents, is giving rise to novel and unexplored challenges, which will cause a significant transformation of the current oncological knowledge in the next few years. The integration of established clinically effective regimens in additional studies will be crucial in managing these innovative aspects of GC. This study aims to present an in-depth and comprehensive review of the clinical advancements in targeted therapy and immunotherapy for advanced GC.